Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 May 1;5(4):513-8.
doi: 10.1513/pats.200708-124ET.

Oxygen therapy in chronic obstructive pulmonary disease

Affiliations
Review

Oxygen therapy in chronic obstructive pulmonary disease

Victor Kim et al. Proc Am Thorac Soc. .

Abstract

Since the introduction of oxygen as a therapeutic agent 70 years ago, much has been learned regarding the detrimental effects of hypoxemia and the beneficial impact of oxygen therapy. It is projected that there are close to 800,000 patients receiving long-term oxygen therapy (LTOT) in the United States, at a cost of approximately $1.8 billion annually. The large numbers of patients receiving supplemental oxygen as treatment and the high costs incurred in providing oxygen therapy necessitate the practitioner to know the indications for LTOT as well its effects on survival, pulmonary hemodynamics, sleep, and exercise capacity. It is now recognized that the basis for LTOT prescription for all patients is founded on data that are over 25 years old and that only involve a very select cohort of patients. It is clear that further studies are required to assess the effects of oxygen on patients with chronic obstructive pulmonary disease with only mild hypoxemia, not only survival but also on neurocognitive function, quality of life, exercise physiology, and sleep quality. In addition, although proven to be safe when prescribed long term to individuals with lung disease, there are some concerns about worsening carbon dioxide retention and increased oxidant injury. The goals of this article are to briefly describe the indications for chronic oxygen administration, the physiologic effects of treatment, and potential toxicities, as well as its effect on morbidity and mortality.

PubMed Disclaimer

Figures

<b>Figure 1.</b>
Figure 1.
Overall mortality in the patients enrolled in the National Oxygen Treatment Trial. Circles (upper curve) represent continuous oxygen therapy group. Squares (lower curve) represent nocturnal oxygen therapy group. Twelve-month mortality in the nocturnal oxygen group was 20.6%, versus 11.9% in the continuous oxygen therapy group. Twenty-four–month mortality in the nocturnal oxygen group was 40.8% versus 22.4% in the continuous oxygen treatment group. Reprinted by permission from Reference .

Similar articles

Cited by

References

    1. O'Donohue WJ Jr, Plummer AL. Magnitude of usage and cost of home oxygen therapy in the United States. Chest 1995;107:301–302. - PubMed
    1. Chronos N, Adams L, Guz A. Effect of hyperoxia and hypoxia on exercise-induced breathlessness in normal subjects. Clin Sci (Lond) 1988;74:531–537. - PubMed
    1. Lane R, Cockcroft A, Adams L, Guz A. Arterial oxygen saturation and breathlessness in patients with chronic obstructive airways disease. Clin Sci (Lond) 1987;72:693–698. - PubMed
    1. Swinburn CR, Mould H, Stone TN, Corris PA, Gibson GJ. Symptomatic benefit of supplemental oxygen in hypoxemic patients with chronic lung disease. Am Rev Respir Dis 1991;143:913–915. - PubMed
    1. Somfay A, Porszasz J, Lee SM, Casaburi R. Dose–response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients. Eur Respir J 2001;18:77–84. - PubMed

Publication types

MeSH terms